Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Jun 1, 2026.

Back to dashboard

CommercialCoverageMedium impact

08.02.40a, Cosibelimab-ipdl (Unloxcyt™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jun 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Independence Blue Cross has implemented new medical necessity criteria for Cosibelimab-ipdl (Unloxcyt™), a specialty pharmaceutical drug. This policy establishes coverage requirements and approval criteria for this medication under commercial plans.

Action Required

Action needed

By June 1, 2026: Review new medical necessity criteria for Cosibelimab-ipdl (Unloxcyt™) prescriptions. Billing team and providers must ensure all documentation requirements are met before prescribing or billing for this medication. Access full policy at medpolicy.ibx.com for specific coverage criteria and prior authorization requirements.

Related policy hubs

Independence Blue Cross policies Oncology Hematology